Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office until the third annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP as the Company's independent auditors

Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2022 annual general meeting of shareholders, which was held on December 21, 2022, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all seven directors to hold office until the next annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP (formerly know

Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced the results of its 2021 annual general meeting of shareholders, which was held on December 2, 2021, in Hong Kong. At the annual general meeting, the required number of shareholders of the Company: Re-elected all of the Company's current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst, Dr. Mirko Scherer, Professor Justin Wu and Professor Douglas Arner as directors of the Company until the Company's next annual general meeting o

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. "Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board ha

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing

ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (NASDAQ:APM, PARIS:APM) and ASP Isotopes Inc. (NASDAQ:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aptorum Group Limited (NASDAQ:APM): https://www.aptoruminfo.com/interview_accessASP Isotopes Inc. (NASDAQ:ASPI): https://aspiinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years

ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(PARIS:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO and Executive Chairman Darren Lui discusses the Company's pipeline for oncology, autoimmune, and infectious diseases, a $15 billion market opportunity, the comp

Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2022. "During the first half of 2022, we remained focused on advancing the development of our therapeutic programs. As announced in early 2022, both our SACT-1 program (targeting neuroblastoma) and ALS-4 program (targeting MRSA), has announced the completion and positive Phase I clinical trial results. Our RPIDD program (liquid biopsy based approach to infectious

ORLANDO, FL / ACCESSWIRE / September 23, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (NASDAQ:APM)(PARIS:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, September 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO Darren Lui discusses the development and commercialization of their novel therapeutics, their diagnostic product, their granted U.S. patents, and much more.Ac

NEW YORK, NY and LONDON, UK, and PARIS, FRANCE / ACCESSWIRE / August 19, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, August 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO Darren Lui discusses the development and commercialization of their novel therapeutics, their diagnostic product, their granted U.

Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2021, and provided an update on clinical and corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented "Aptorum's operational plans remain on track. In particular, our lead projects, ALS-4 (targeting infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)) and SACT-1 (targeting neuroblast

Regulatory News: Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM))) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2021. "During the first half of 2021, we remained focused on advancing the development of our therapeutic programs. As announced in early 2021, our ALS-4 program (targeting infections caused by Staphylococcus aureus including MRSA) commenced a Phase 1 clinical study in Canada. We are pleased that 5 total cohorts, which represent the essential part of the single as

Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until 14 October 2025, to regain compliance with the continued listing requirements. During this period, Aptorum Group Limited intends to evaluate all available options to restore

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the "Ordinary Shares") in a registered direct offering. The ordinary shares are being sold at an offering price of $2.00 per share. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $3.0 million before deducting the placement agent's fees

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. "Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board ha

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented, "Throughout 2023, we have maintained a strategic focus on the progression of our lead projects to effectively utilize our resources. Additionally, the previously announced proposed reverse merger with YOOV Group Holding demonstrates our commitment to shareholder interests a

Aptorum Group Limited (NASDAQ:APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"). The Merger Agreement was approved by Aptorum's and YOOV's boards of directors (each board of directors, the "Board"), respectively. If the Merger Agreement is approved by Aptorum's and YOOV's shareholders (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing", and the da

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office until the third annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP as the Company's independent auditors

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2023 annual general meeting of shareholders at its London office located at 17 Hanover Square, Mayfair London, England W1S 1BN at 1:00 p.m. London Time on December 20, 2023 (8:00 a.m. Eastern Standard Time on December 20, 2023). Shareholders of record as of November 10, 2023 are entitled to receive notice of and vote at the annual general meeting. Aptorum filed its annual report on Form 20-F, including its audited financial statements for the fis

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market. On this basis, the previous two listing deficiencies regarding minimum stockholder's equity and minimum market value of publicly held shares will be closed. The trading of its Class A ordinary shares will continue on Nasdaq and will not be affected.   About Aptorum Group Aptorum Group Limited (NASDAQ:A

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA. The Phase 1b/2a study of SACT-1 submitted is for the combination with chemotherapy for first relapse or refractory high risk neuroblastoma. Mr. Darren Lui, Chief Executive Officer of Aptorum Group, commented, "Pursuant to an IND opened in September 2021, we have recently submitted a clinical protocol for a P

SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

SC 13G/A - Aptorum Group Ltd (0001734005) (Subject)

SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

SC 13G - Aptorum Group Ltd (0001734005) (Subject)

SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

SC 13G - Aptorum Group Ltd (0001734005) (Subject)